Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabozantinib derivative 5
- Development stage
- Unknown
- Lead developer
- Exelixis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cabozantinib derivative 5 appears to refer to a research compound that is a chemical derivative of cabozantinib, an oral small molecule tyrosine kinase inhibitor used to treat a range of cancers including renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. The parent compound, cabozantinib, blocks multiple receptor tyrosine kinases such as VEGFR-1, VEGFR-2, VEGFR-3, MET, AXL, RET, ROS1, KIT, TRKB, FLT-3, and TIE-2, all implicated in tumor growth, angiogenesis, metastasis, and maintenance of the tumor microenvironment[1][3][5][7]. No specific data is available in these sources concerning the pharmacological properties, unique mechanism, formulation, or clinical development of the compound specifically named "cabozantinib derivative 5."
02
Targets
AXL (AXL receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)ER-XMET (Mesenchymal-epithelial transition factor receptor)RET (Rearranged during transfection receptor tyrosine kinase)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)TEK (Tie2)NTRK2 (Tropomyosin-related kinase receptor type B)UGT1A9 (UDP-glucuronosyltransferase 1A9)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)MERTK (MER proto-oncogene, tyrosine kinase)
Beyond the preview
Go deeper on cabozantinib derivative 5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabozantinib derivative 5.